Form 8-K - Current report:
SEC Accession No. 0001140361-22-044598
Filing Date
2022-12-06
Accepted
2022-12-06 16:30:55
Documents
12
Period of Report
2022-11-30
Items
Item 1.02: Termination of a Material Definitive Agreement

Document Format Files

Seq Description Document Type Size
1 8-K brhc10045139_8k.htm   iXBRL 8-K 25794
  Complete submission text file 0001140361-22-044598.txt   161789

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA erna-20221130.xsd EX-101.SCH 3866
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE erna-20221130_lab.xml EX-101.LAB 22547
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE erna-20221130_pre.xml EX-101.PRE 16045
6 EXTRACTED XBRL INSTANCE DOCUMENT brhc10045139_8k_htm.xml XML 4238
Mailing Address 10355 SCIENCE CENTER DRIVE SUITE 150 SAN DIEGO CA 92121
Business Address 10355 SCIENCE CENTER DRIVE SUITE 150 SAN DIEGO CA 92121 (212) 582-1199
Eterna Therapeutics Inc. (Filer) CIK: 0000748592 (see all company filings)

EIN.: 311103425 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-11460 | Film No.: 221448148
SIC: 2834 Pharmaceutical Preparations